BIOLINERX LTD/S (NASDAQ:BLRX) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.33 and traded as high as $2.90. BIOLINERX LTD/S shares last traded at $2.85, with a volume of 9,630 shares traded.
A number of analysts have recently issued reports on the stock. Maxim Group reaffirmed a “buy” rating and set a $10.00 price objective on shares of BIOLINERX LTD/S in a report on Monday, July 22nd. ValuEngine downgraded shares of BIOLINERX LTD/S from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. HC Wainwright reaffirmed a “neutral” rating on shares of BIOLINERX LTD/S in a report on Wednesday, August 7th. Finally, Zacks Investment Research downgraded shares of BIOLINERX LTD/S from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $4.13.
The company has a current ratio of 4.23, a quick ratio of 4.23 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $21.69 million, a P/E ratio of -0.89 and a beta of 1.60. The business’s fifty day moving average price is $3.10 and its 200-day moving average price is $1.33.
BIOLINERX LTD/S (NASDAQ:BLRX) last posted its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.61. As a group, equities research analysts forecast that BIOLINERX LTD/S will post -2.69 EPS for the current year.
Large investors have recently modified their holdings of the stock. Deutsche Bank AG purchased a new position in BIOLINERX LTD/S in the 4th quarter worth $26,000. NEXT Financial Group Inc raised its position in BIOLINERX LTD/S by 82.5% in the 2nd quarter. NEXT Financial Group Inc now owns 73,000 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 33,000 shares during the period. Delek Group Ltd. purchased a new position in BIOLINERX LTD/S in the 1st quarter worth $92,000. Finally, Morgan Stanley raised its position in BIOLINERX LTD/S by 50.6% in the 2nd quarter. Morgan Stanley now owns 1,421,862 shares of the biotechnology company’s stock worth $519,000 after purchasing an additional 477,798 shares during the period.
BIOLINERX LTD/S Company Profile (NASDAQ:BLRX)
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.
Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.